Unlocking the New
GLP-1 Landscape
A 360° view of the real GLP-1 market pulse & decision-making process, powered by advanced analytics and AI.
A 360° view of the real GLP-1 market pulse & decision-making process, powered by advanced analytics and AI.
85% of HCPs view Mounjaro’s weight loss benefits as superior to Ozempic’s 75%, with weight loss now equally important as A1C reduction in T2D treatment selection.
Weight loss influences 11% of T2D decisions while cardiovascular benefits drive 12%—nearly equal consideration as HCPs seek GLP-1 treatment addressing multiple patient needs.
75% associate semaglutide with CV benefits vs. 46% for tirzepatide, with 62% of Ozempic prescribing driven by CV considerations compared to 41% for Mounjaro.
3 in 4 HCPs cite cost and coverage restrictions as leading GLP-1 agonist treatment barriers, with >10% abandoning clinically preferred treatments due to access issues.
Despite even traditional rep activity (42% share each), Eli Lilly achieves highest digital reach with Zepbound leading banner ad engagement and capturing growing weight-loss HCP browsing time.
While HCPs show strong recognition of established players expanding into new territories, >50% of HCPs are unaware of other pipeline options in core metabolic indications.
To capture a full spectrum of HCP perspectives on GLP-1s and to help life-science leaders navigate this wave, ZoomRx launched a 3-part rapid, integrated study that asked the 3 big questions:
Obesity and T2D care are being rewritten by GLP-1 agonists. Injectable blockbusters have gone mainstream, oral contenders are in Phase 3, and weight-loss demand is straining supply chains.
When mind-set (ATU), influence (PET), and action (PCA) line up, you get a 360° playbook that lets commercial, medical, and access teams:
Lead every message with weight-loss efficacy—now as pivotal as glycemic control.
Shift budget to the online channels that out-perform TV on HCP recall and engagement.
Equip reps with authentic patient narratives that bring campaign claims to life at the bedside.
AI-driven solutions that take you from insight gathering to market action—faster, deeper, smarter.
A collection of AI-powered market-research tools that lets pharma teams design, field, and analyze quant-and-qual studies in a single, friction-free workflow.
Voice-first chart audits with >90 % verbatim accuracy and instant NLP theme tagging, capturing the clinical “why” no survey can reach.
24/7 surveillance of every HCP-facing ad—brand, channel, creative, and spend—so you see competitive moves as they happen.
Unlock the complete data set or talk it through with our experts— your next move starts here.
TALK TO US
